Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 4/20 | 0.53 |
| ▸ | FYN | P06241 | 7/20 | 0.50 |
| ▸ | DYRK3 | O43781 | 2/20 | 0.48 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.48 |
| ▸ | CDK2 | P24941 | 2/20 | 0.48 |
| ▸ | CDK9 | P50750 | 2/20 | 0.48 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.48 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.48 |
| ▸ | DYRK2 | Q92630 | 2/20 | 0.48 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.48 |
| ▸ | CAMK2D | Q13557 | 2/20 | 0.46 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3876350 | 0.88 | PIM1 (0.52) | PIM1FYNDYRK3CCNT1CCNA2 | |
| SCHEMBL3868868 | 0.88 | PIM1 (0.52) | PIM1FYNDYRK3CCNT1CCNA2 | |
| SCHEMBL14373144 | 0.88 | FYN (0.54) | PIM1FYNMKNK1 | |
| SCHEMBL3876095 | 0.88 | DYRK3 (0.56) | PIM1FYNDYRK3CCNT1CCNA2 | |
| SCHEMBL3869808 | 0.87 | FYN (0.51) | PIM1FYNDYRK3CCNA2CDK2 | |
| SCHEMBL3869936 | 0.87 | DYRK1A (0.67) | PIM1FYNDYRK3CCNT1CCNA2 | |
| SCHEMBL3865452 | 0.87 | CAMK2D (0.48) | PIM1FYNDYRK3CCNT1CCNA2 | |
| SCHEMBL3863893 | 0.87 | FYN (0.57) | PIM1FYN | |
| SCHEMBL3874342 | 0.87 | PIM1 (0.59) | PIM1FYNDYRK3CCNT1CCNA2 | |
| SCHEMBL3864543 | 0.86 | FYN (0.46) | PIM1FYNDYRK3CCNT1CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140135323-A1 | OXO-SUBSTITUTED IMIDAZO[1,2B]PYRIDAZINES, THEIR PREPARATION AND USE AS PHARMACEUTICALS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-05-15 | — | — | US | claimed |
| US-8653076-B2 | Oxo-substituted imidazo[1,2B]pyridazines, their preparation and use as pharmaceuticals | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-18 | — | — | US | claimed |
| US-20090093475-A1 | Oxo-substituted imidazo[1,2b]pyridazines, their preparation and use as pharmaceuticals | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-04-09 | — | — | US | claimed |
| EP-2044071-A1 | OOXO-SUBSTITUTED IMIDAZO[1,2b]PYRIDAZINES, PRODUCTION AND USE THEREOF AS DRUGS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-04-08 | — | — | EP | claimed |
| WO-2007147646-A1 | OXO-SUBSTITUTED IMIDAZO[1,2b]PYRIDAZINES, PRODUCTION AND USE THEREOF AS DRUGS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-12-27 | — | — | WO | claimed |
| US-20140135323-A1 | OXO-SUBSTITUTED IMIDAZO[1,2B]PYRIDAZINES, THEIR PREPARATION AND USE AS PHARMACEUTICALS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-05-15 | — | — | US | disclosed |
| US-20140135323-A1 | OXO-SUBSTITUTED IMIDAZO[1,2B]PYRIDAZINES, THEIR PREPARATION AND USE AS PHARMACEUTICALS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-05-15 | — | — | US | disclosed |
| US-8653076-B2 | Oxo-substituted imidazo[1,2B]pyridazines, their preparation and use as pharmaceuticals | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-18 | — | — | US | disclosed |
| US-8653076-B2 | Oxo-substituted imidazo[1,2B]pyridazines, their preparation and use as pharmaceuticals | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-18 | — | — | US | disclosed |
| US-20090093475-A1 | Oxo-substituted imidazo[1,2b]pyridazines, their preparation and use as pharmaceuticals | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-04-09 | — | — | US | disclosed |
| US-20090093475-A1 | Oxo-substituted imidazo[1,2b]pyridazines, their preparation and use as pharmaceuticals | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093475-A1 | Oxo-substituted imidazo[1,2b]pyridazines, their preparation and use as pharmaceuticals | CDK2, CDK1, MAP4K2 | PIM1 712/4885FYN 363/4885DYRK3 491/4885 |
| US-20140135323-A1 | OXO-SUBSTITUTED IMIDAZO[1,2B]PYRIDAZINES, THEIR PREPARATION AND USE AS PHARMACEUTICALS | CDK2, CDK1, MAP4K2 | PIM1 712/4885FYN 363/4885DYRK3 491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.